Evidence for atrophy and apoptosis in the prostates of men given finasteride

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 2, 1996, Pages 814-819

  Rittmaster, Roger S ^a,b   Norman, Richard W ^a   Thomas, Lynn N ^a   Rowden, Geoffrey ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Gerard Hall ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE;

APOPTOSIS; ARTICLE; ATROPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY;

APOPTOSIS; ATROPHY; DIHYDROTESTOSTERONE; DNA; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EPITHELIUM; FINASTERIDE; HUMANS; MALE; PLACEBOS; PROSTATE; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSGLUTAMINASES;

EID: 0030021726     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.2.814     Document Type: Article

References (30)

1. Rasmusson GH, Reynolds GF, Steinberg NG, et al. 1986 Azasteroids: structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding. J Med Chem. 29:2298-2315.
2. Rittmaster RS. 1994 Finasteride. N Engl J Med. 330:120-125.
3. Gormley GJ, Stoner E, Bruskewitz RC, et al. 1992 The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1185-1191.
4. Stoner E, Finasteride Study Group. 1994 Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 43:284-294.
5. Kyprianou N, Isaacs JT. 1988 Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology. 122:552-562.
6. Rouleau M, Leger J, Tenniswood M. 1990 Ductal heterogeneity of cytokeratins, gene expression, and cell death in the rat ventral prostate. Mol Endocrinol. 4:2003-2013.
7. Kyprianou N, English HF, Isaacs JT. 1990 Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 50:3748-3753.
8. Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK, Isaacs JT. 1992 Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F 105657:role for testosterone in the androgenic response. Endocrinology. 130: 685-694.
9. Lamb JC, Levy MA, Johnson RK, Isaacs JT. 1992 Response of rat and human prostatic cancers to the novel 5α-reductase inhibitor, SK&F 105657. Prostate 21:0000-0000.
10. Schwartzman RA, Cidlowski JA. 1993 Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocr Rev. 14:133-151.
11. Rittmaster RS, Magor KE, Manning AP, Norman RW, Lazier CB. 1991 Differential effect of 5α-reductase inhibition and castration on androgen-regulated gene expression in rat prostate. Mol Endocrinol. 5:1023-1029.
12. McConnell JD, Wilson JD, George FW, Geller G, Pappas F, Stoner E. 1992 Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 74:505-508.
13. Shao TC, Kong A, Marafelia P, Cunningham GR. 1993 Effects of finasteride on the rat ventral prostate. J Androl. 14:79-86.
14. Geller J. 1990 Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab. 71:1552-1555.
15. Rittmaster RS, Manning AP, Wright AS, et al. 1995 Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology 136:0000-0000.
16. Fesus L, Davies PJA, Piacentini M. 1991 Apoptosis: molecular mechanisms in programmed cell death. Eur J Cell Biol. 56:170-177.
17. Piacentini M, Autuori F, Dini L, et al. 1991 "Tissue" transglutaminase is specifically expressed in neonatal rat liver cells undergoing apoptosis upon epidermal growth factor-stimulation. Cell Tissue Res. 263:227-235.
18. Gavrieli Y, Sherman Y, Ben-Sasson SA. 1992 Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:493-501.
19. Wijsman JH, Jonker RR, Keijzer R, Van De Velde CJH, Cornelisse CJ, Van Dierendonck JH. 1993 A new method to detect apoptosis in paraffin sections: In situ end-labeling of fragmented DNA. J Histochem Cytochem. 41:7-12.
20. Norman RW, Coakes KE, Wright AS, Rittmaster RS. 1993 Androgen metabolism in men receiving finasteride prior to prostatectomy. J Urol. 150:1736-1739.
21. Huggins C, Stevens RA. 1940 The effect of castration on benign hypertrophy of the prostate in man. J Urol. 43:705-714.
22. Peters CA, Walsh PC. 1987 The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 317:599-604.
23. Imperato-McGinley J, Gautier T, Zirinsky K, et al. 1992 Prostate visualization studies in males homozygous and heterozygous for 5α-reductase deficiency. J Clin Endocrinol Metab. 75:1022-1026.
24. Stoner E, Finasteride Study Group. 1992 The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol. 147:1298-1302.
25. Finasteride Study Group. 1993 Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22:291-299.
26. Tammela TLJ, Kontturi MJ. 1993 Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol. 149:342-344.
27. Thompson EB. 1994 Apoptosis and steroid hormones. Mol Endocrinol. 8:665-673.
28. Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT. 1993 Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA. 90:8910-8914.
29. Laroque PA, Prahalada S, Gordon LR, et al. 1994 Effects of chronic oral administration of a selective 5α-reductase inhibitor, finasteride, on the dog prostate. Prostate. 24:93-100.
30. Deering RE, Choongkittaworn M, Bigler SA, Aramburu E, King J, Brawer MK. 1994 Morphometric quantitation of stroma in human benign prostatic hyperplasia. Urology. 44:64-70.